Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Therapeutic Drug Monitoring
99%
Multi-Drug-Resistant Tuberculosis
60%
Linezolid
30%
Tuberculostatic Agent
28%
Rifampicin
27%
Voriconazole
27%
Pharmacodynamics
25%
Extensively Drug-Resistant Tuberculosis
22%
Moxifloxacin
20%
Bedaquiline
16%
Pyrazinamide
15%
Levofloxacin
15%
Clarithromycin
14%
Infection
14%
Adverse Event
14%
Drug Resistant Tuberculosis
14%
Ethambutol
14%
Antifungal Agent
14%
Mycobacterium Tuberculosis
14%
Antiinfective Agent
13%
Inflammation
12%
Fluconazole
12%
Isoniazid
12%
Disease
11%
Posaconazole
11%
HIV
11%
Amikacin
10%
Ganciclovir
10%
Pharmacokinetic Modeling
10%
Drug Resistance
10%
Drug Concentration
9%
Cohort Study
9%
Quinolone Derivative
9%
Invasive Candidiasis
8%
Randomized Controlled Trial
8%
Clavulanic Acid
7%
Anidulafungin
7%
Caspofungin
7%
Adverse Drug Reaction
7%
Minimum Inhibitory Concentration
7%
Tolerability
7%
Ertapenem
7%
Elimination
7%
Normal Human
6%
Prospective Study
6%
Delamanid
6%
Toxic Hepatitis
6%
Clinical Study
6%
Cotrimoxazole
6%
Keyphrases
Therapeutic Drug Monitoring
33%
Multidrug-resistant Tuberculosis (MDR-TB)
24%
Pharmacokinetics
21%
Tuberculosis
17%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
11%
Rifampicin
11%
Critically Ill Patients
11%
Restricted Sampling
10%
Pyrazinamide
10%
Voriconazole
9%
Tuberculosis Patients
8%
Bedaquiline
8%
Tuberculosis Drugs
7%
Pharmacokinetics-pharmacodynamics (PK-PD)
7%
Invasive Candidiasis
7%
Linezolid
7%
Anti-tuberculosis Drugs
7%
TB Patients
7%
Ganciclovir
7%
Population Pharmacokinetic Model
7%
Delamanid
6%
High Dose
6%
Area under the Concentration-time Curve
6%
Systematic Meta-analysis
5%
Tuberculosis Treatment
5%
Moxifloxacin
5%
First-line Anti-tuberculosis Drugs
5%
Adverse Events
5%
Pharmacokinetic Modeling
5%
Rifampin
5%
Anidulafungin
5%
Optimal Sample Size
5%
Tobramycin
5%
Kanamycin
5%
Ethambutol
5%
Medicine and Dentistry
Multidrug Resistant Tuberculosis
26%
Therapeutic Drug Monitoring
18%
Tuberculosis Treatment
13%
Extensively Drug Resistant Tuberculosis
13%
Bedaquiline
12%
Systematic Review
11%
Drug Resistant Tuberculosis
10%
Human Immunodeficiency Virus
9%
Infection
8%
COVID-19
8%
Health Care Cost
7%
Delamanid
7%
Adverse Event
7%
Linezolid
7%
Disease
6%
Meta-Analysis
6%
Clavulanic Acid
5%
Meropenem
5%
Public Health
5%
Tuberculostatic Agent
5%
Mycobacterium Tuberculosis
5%
Diagnosis
5%